Sep 28, 2020 / 12:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics Clinical Updates: Gene Therapy Programs Presentation. (Operator Instructions) As a reminder, today's program is being recorded. And now I'll turn the call over to Doug Ingram, President and CEO, for opening remarks. Please go ahead.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Good morning, everybody, and thank you for joining us this morning as we provide some clinical updates for our 2 most advanced gene therapy programs, SRP-9001 and SRP-9003. This is Doug Ingram. I am the CEO of Sarepta. I am going to turn over the call momentarily to Dr. Louise Rodino-Klapac, who will go through updates on both of those programs.
Before I do, I would remind you that we will very likely, either in the main presentation or in the Q&A, make some forward-looking statements or, in other words, some potential statements about future events. One should review our public filings for a full list of the risks that are attendant whenever one attempts to make
Sarepta Therapeutics Inc Conference Call to Discuss Long-term Functional Data from Gene Therapy Programs to be Presented at WMS25 Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
